Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint

Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 665 · see citing works

The core Dravet syndrome phenotype

Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 630 · see citing works

Mortality in Dravet syndrome

Cooper, M. S., McIntosh, A. M., Crompton, D. E., McMahon, J. M., Schneider, A., Farrell, K., Ganesan, V., Gill, D. S., Kivity, S., Lerman‐Sagie, T., et al. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.10.006 · Cited by 320 · see citing works

Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel

Wirrell, E. C., Laux, L., Donner, E. J., Jetté, N., Knupp, K. G., Meskis, M. A., Miller, I., Sullivan, J. E., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 287 · see citing works

The genetics of Dravet syndrome

Marini, C., Scheffer, I. E., Nabbout, R., Suls, A., Jonghe, P. D., Zara, F., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02997.x · Cited by 274 · see citing works

Incidence of Dravet Syndrome in a US Population

Wu, Y. W., Sullivan, J., McDaniel, S. S., Meisler, M. H., Walsh, E. M., Li, S. X., & Kuzniewicz, M. W. (2015) · Pediatrics · doi:10.1542/peds.2015-1807 · Cited by 248 · see citing works

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 242 · see citing works

dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice

Colasante, G., Lignani, G., Brusco, S., Berardino, C. D., Carpenter, J. C., Giannelli, S. G., Valassina, N., Bido, S., Ricci, R., Castoldi, V., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.018 · Cited by 236 · see citing works

Cannabinoids in treatment-resistant epilepsy: A review

O’Connell, B. K., Gloss, D. S., & Devinsky, O. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.012 · Cited by 228 · see citing works

The SCN1A Mutation Database: Updating Information and Analysis of the Relationships among Genotype, Functional Alteration, and Phenotype

Meng, H., Xu, H., Yu, L., Lin, G., He, N., Su, T., Shi, Y., Li, B., Wang, J., Liu, X., et al. (2015) · Human Mutation · doi:10.1002/humu.22782 · Cited by 205 · see citing works

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Lim, K., Zhou, H., Jeon, H. Y., Kach, J., Jing, E., Weyn‐Vanhentenryck, S. M., Downs, M., Corrionero, A., Oh, R. S., Scharner, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17093-9 · Cited by 203 · see citing works

From genotype to phenotype in Dravet disease

Gataullina, S., & Dulac, O. (2016) · Seizure · doi:10.1016/j.seizure.2016.10.014 · Cited by 179 · see citing works

Oligonucleotide therapies for disorders of the nervous system

Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179 · see citing works

Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice

Mistry, A. M., Thompson, C. H., Miller, A. R., Vanoye, C. G., George, A. L., & Kearney, J. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.006 · Cited by 177 · see citing works

Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief

Skluzacek, J. V., Watts, K. P., Parsy, O., Wical, B., & Camfield, P. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03012.x · Cited by 170 · see citing works

Not all <i>SCN1A</i> epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype

Sadleir, L. G., Mountier, E. I., Gill, D., Davis, S., Joshi, C., DeVile, C., Kurian, M. A., Study, F. T. D., Mandelstam, S., Wirrell, E., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004331 · Cited by 131 · see citing works

TheSCN1Avariant database: a novel research and diagnostic tool

Claes, G. R. F., Deprez, L., Suls, A., Baets, J., Smets, K., Dyck, T. V., Deconinck, T., Jordanova, A., & Jonghe, P. D. (2009) · Human Mutation · doi:10.1002/humu.21083 · Cited by 128 · see citing works

Nonintegrating Gene Therapy Vectors

Athanasopoulos, T., Munye, M. M., & Yáñez‐Muñoz, R. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.007 · Cited by 128 · see citing works

Aberrant Inclusion of a Poison Exon Causes Dravet Syndrome and Related SCN1A-Associated Genetic Epilepsies

Carvill, G. L., Engel, K. L., Ramamurthy, A., Cochran, J. N., Roovers, J., Stamberger, H., Lim, N. T. Y., Schneider, A., Hollingsworth, G., Holder, D. H., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.10.023 · Cited by 119 · see citing works

SCN1A gain of function in early infantile encephalopathy

Berecki, G., Bryson, A., Terhag, J., Maljevic, S., Gazina, E. V., Hill, S., & Petrou, S. (2019) · Annals of Neurology · doi:10.1002/ana.25438 · Cited by 94 · see citing works

Epileptic Encephalopathies with Myoclonic Seizures in Infants and Children (Severe Myoclonic Epilepsy and Myoclonic-Astatic Epilepsy)

Guerrini, R., & Aicardi, J. F. (2003) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200311000-00007 · Cited by 92 · see citing works

Nonsense-mediated mRNA decay at the crossroads of many cellular pathways

Lejeune, F. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.4.015 · Cited by 82 · see citing works

Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later

Dravet, C., Bureau, M., Bernardina, B. D., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02993.x · Cited by 78 · see citing works

Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq

Hawkins, N. A., Zachwieja, N. J., Miller, A. R., Anderson, L. L., & Kearney, J. A. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006398 · Cited by 71 · see citing works

Cacna1g is a genetic modifier of epilepsy in a mouse model of Dravet syndrome

Calhoun, J. D., Hawkins, N. A., Zachwieja, N. J., & Kearney, J. A. (2017) · Epilepsia · doi:10.1111/epi.13811 · Cited by 58 · see citing works

Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells

Gérard, X., Perrault, I., Münnich, A., Kaplan, J., & Rozet, J. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.24 · Cited by 34 · see citing works

Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome

Buck, M. L., & Goodkin, H. P. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019856008 · Cited by 30 · see citing works

Emerging drugs for the treatment of Dravet syndrome

Brigo, F., Striano, P., Balagura, G., & Belcastro, V. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1552937 · Cited by 28 · see citing works

Chronic Toxicity Assessment of 2′- O -Methoxyethyl Antisense Oligonucleotides in Mice

Zanardi, T. A., Kim, T., Shen, L., Serota, D. G., Papagiannis, C. N., Park, S., Kim, Y., & Henry, S. P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0706 · Cited by 22 · see citing works

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

Lauffer, M. C., van Roon‐Mom, W., Aartsma-Rus, A. M., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 289 · see citing works

International consensus on diagnosis and management of Dravet syndrome

Wirrell, E. C., Hood, V., Knupp, K. G., Meskis, M. A., Nabbout, R., Scheffer, I. E., Wilmshurst, J., & Sullivan, J. (2022) · Epilepsia · doi:10.1111/epi.17274 · Cited by 249 · see citing works

Sodium channelopathies in neurodevelopmental disorders

Meisler, M. H., Hill, S. F., & Yu, W. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00418-4 · Cited by 202 · see citing works

Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum

Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196 · see citing works

The gain of function <i>SCN1A</i> disorder spectrum: novel epilepsy phenotypes and therapeutic implications

Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J., Arzimanoglou, A., et al. (2022) · Brain · doi:10.1093/brain/awac210 · Cited by 167 · see citing works

Oligonucleotide Therapeutics: From Discovery and Development to Patentability

Moumné, L., Marie, A., & Crouvezier, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020260 · Cited by 137 · see citing works

New epilepsy therapies in development

Klein, P., Kaminski, R. M., Koepp, M. J., & Löscher, W. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00981-w · Cited by 159 · see citing works

Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress

Knowles, J. K., Helbig, I., Metcalf, C. S., Lubbers, L. S., Isom, L. L., Demarest, S., Goldberg, E. M., George, A. L., Lerche, H., Weckhuysen, S., et al. (2022) · Epilepsia · doi:10.1111/epi.17332 · Cited by 149 · see citing works

Sodium channelopathies of skeletal muscle and brain

Mantegazza, M., Cestèle, S., & Catterall, W. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00025.2020 · Cited by 133 · see citing works

Amplifying gene expression with RNA-targeted therapeutics

Khorkova, O., Stahl, J., Joji, A., Volmar, C., & Wahlestedt, C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00704-7 · Cited by 132 · see citing works

Developmental and epileptic encephalopathies

Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 128 · see citing works

Cell-Selective Adeno-Associated Virus-Mediated <i>SCN1A</i> Gene Regulation Therapy Rescues Mortality and Seizure Phenotypes in a Dravet Syndrome Mouse Model and Is Well Tolerated in Nonhuman Primates

Tanenhaus, A., Stowe, T., Young, A., McLaughlin, J., Aeran, R., Lin, I. W., Li, J., Hosur, R., Chen, M., Leedy, J., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.037 · Cited by 124 · see citing works

Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials

Li, W., Schneider, A. L., & Scheffer, I. E. (2021) · Epilepsia · doi:10.1111/epi.17015 · Cited by 123 · see citing works

A perspective on oligonucleotide therapy: Approaches to patient customization

Thakur, S., Sinhari, A., Jain, P., & Jadhav, H. R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006304 · Cited by 114 · see citing works

Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model

Li, M., Jancovski, N., Jafar-Nejad, P., Burbano, L. E., Rollo, B., Richards, K., Drew, L., Sedo, A., Heighway, J., Pachernegg, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152079 · Cited by 115 · see citing works

Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies

Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012744 · Cited by 108 · see citing works

Gene variant effects across sodium channelopathies predict function and guide precision therapy

Brunklaus, A., Feng, T., Brünger, T., Pérez‐Palma, E., Heyne, H., Matthews, E. L., Semsarian, C., Symonds, J. D., Zuberi, S. M., Lal, D., et al. (2022) · Brain · doi:10.1093/brain/awac006 · Cited by 105 · see citing works

Current knowledge of SLC6A1-related neurodevelopmental disorders

Goodspeed, K., Pérez‐Palma, E., Iqbal, S., Cooper, D. D., Scimemi, A., Johannesen, K. M., Stefanski, A., Demarest, S., Helbig, K. L., Kang, J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa170 · Cited by 102 · see citing works

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics

Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96 · see citing works

Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy

Bayat, A., Bayat, M., Rubboli, G., & Møller, R. S. (2021) · Genes · doi:10.3390/genes12071051 · Cited by 98 · see citing works

Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe

Cardenal‐Muñoz, E., Auvin, S., Villanueva, V., Cross, J. H., Zuberi, S. M., Lagae, L. G., & Aibar, J. Á. (2021) · Epilepsia Open · doi:10.1002/epi4.12569 · Cited by 95 · see citing works

The pharmacological treatment of epilepsy: recent advances and future perspectives

Perucca, E. (2021) · Acta Epileptologica · doi:10.1186/s42494-021-00055-z · Cited by 93 · see citing works

Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders

Hill, S. F., & Meisler, M. H. (2021) · Developmental Neuroscience · doi:10.1159/000517686 · Cited by 91 · see citing works

RNA-based therapeutics for neurological diseases

Anthony, K. (2022) · RNA Biology · doi:10.1080/15476286.2021.2021650 · Cited by 92 · see citing works

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Jensen, T. L., Gøtzsche, C. R., & Woldbye, D. P. D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.695937 · Cited by 85 · see citing works

Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome

Valassina, N., Brusco, S., Salamone, A., Serra, L., Luoni, M., Giannelli, S. G., Bido, S., Massimino, L., Ungaro, F., Mazzara, P. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27837-w · Cited by 78 · see citing works

Development and Validation of a Prediction Model for Early Diagnosis of SCN1A -Related Epilepsies

Brunklaus, A., Pérez‐Palma, E., Ghanty, I., Ji, X., Brilstra, E. H., Ceulemans, B., Chémaly, N., Lange, I., Depienne, C., Guerrini, R., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200028 · Cited by 78 · see citing works

Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology

Amanat, M., Nemeth, C. L., Fine, A. S., Leung, D. G., & Fatemi, A. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112389 · Cited by 76 · see citing works

Modelling epilepsy in the mouse: challenges and solutions

Marshall, G. F., Gonzalez‐Sulser, A., & Abbott, C. M. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.047449 · Cited by 73 · see citing works

Antisense oligonucleotide therapy for KCNT1 encephalopathy

Burbano, L. E., Li, M., Jancovski, N., Jafar-Nejad, P., Richards, K., Sedo, A., Soriano, A., Rollo, B., Jia, L., Gazina, E. V., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.146090 · Cited by 80 · see citing works

Developmentally regulated impairment of parvalbumin interneuron synaptic transmission in an experimental model of Dravet syndrome

Kaneko, K., Currin, C. B., Goff, K. M., Wengert, E. R., Somarowthu, A., Vogels, T. P., & Goldberg, E. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110580 · Cited by 72 · see citing works

Voltage-gated sodium channels in excitable cells as drug targets

Alsaloum, M., Dib‐Hajj, S. D., Page, D. A., Ruben, P. C., Krainer, A. R., & Waxman, S. G. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01108-x · Cited by 66 · see citing works

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

Anderson, L. L., Heblinski, M., Absalom, N. L., Hawkins, N. A., Bowen, M. T., Benson, M. J., Zhang, F., Bahceci, D., Doohan, P. T., Chebib, M., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15661 · Cited by 69 · see citing works

Upregulation of SYNGAP1 expression in mice and human neurons by redirecting alternative splicing

Yang, R., Feng, X., Arias‐Cavieres, A., Mitchell, R. M., Polo, A., Hu, K., Zhong, R., Qi, C., Zhang, R. S., Westneat, N., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.02.021 · Cited by 62 · see citing works

Drug-resistant epilepsy — time to target mechanisms

Lerche, H. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00419-y · Cited by 66 · see citing works

Opportunities and challenges for microRNA-targeting therapeutics for epilepsy

Morris, G., O’Brien, D., & Henshall, D. C. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.007 · Cited by 65 · see citing works

Widespread genomic influences on phenotype in Dravet syndrome, a ‘monogenic’ condition

Martins Custodio, H., Clayton, L. M., Bellampalli, R., Pagni, S., Silvennoinen, K., Caswell, R., Genomics England Research Consortium, Ambrose, J. C., Arumugam, P., Bevers, R., et al. (2023) · Brain · doi:10.1093/brain/awad111 · Cited by 62 · see citing works

Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome

Wengert, E. R., Wagley, P. K., Strohm, S. M., Reza, N., Wenker, I. C., Gaykema, R. P. A., Christiansen, A., Liau, G., & Patel, M. K. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147743 · Cited by 60 · see citing works

Developmental dynamics of voltage-gated sodium channel isoform expression in the human and mouse brain

Liang, L., Darbandi, S. F., Pochareddy, S., Gulden, F. O., Gilson, M. C., Sheppard, B. K., Sahagun, A., An, J., Werling, D. M., Rubenstein, J. L. R., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00949-0 · Cited by 59 · see citing works

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides

Aartsma-Rus, A. M., Garanto, A., van Roon‐Mom, W., McConnell, E. M., Suslovitch, V., Yan, W. X., Watts, J. K., Yu, T. W., & Collaborative, O. B. O. T. N. =. 1. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0060 · Cited by 58 · see citing works

Genetic therapeutic advancements for Dravet Syndrome

Chilcott, E. M., Diaz, J. F. A., Bertram, C., Berti, M., & Karda, R. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108741 · Cited by 60 · see citing works

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development

Perucca, E., White, H. S., & Bialer, M. (2023) · CNS Drugs · doi:10.1007/s40263-023-01025-4 · Cited by 56 · see citing works

TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model

Shao, E., Chang, C.-W., Li, Z., Yu, X., Ho, K., Zhang, M., Wang, X., Simms, J., Lo, I., Speckart, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm5527 · Cited by 54 · see citing works

Dravet syndrome: Advances in etiology, clinical presentation, and treatment

He, Z., Li, Y., Zhao, X., & Li, B. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.107041 · Cited by 57 · see citing works

Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model

Yuan, Y., Lopez‐Santiago, L. F., Denomme, N., Chen, C., O’Malley, H. A., Hodges, S. L., Ji, S., Zhou, H., Christiansen, A., & Isom, L. L. (2023) · Brain · doi:10.1093/brain/awad349 · Cited by 54 · see citing works

Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease

Ahonen, S., Nitschke, S., Grossman, T. R., Kordasiewicz, H. B., Wang, P., Zhao, X., Guisso, D. R., Kasiri, S., Nitschké, F., & Minassian, B. A. (2021) · Brain · doi:10.1093/brain/awab194 · Cited by 53 · see citing works

Corticohippocampal circuit dysfunction in a mouse model of Dravet syndrome

Mattis, J., Somarowthu, A., Goff, K. M., Jiang, E., Yom, J., Sotuyo, N. P., McGarry, L. M., Feng, H., Kaneko, K., & Goldberg, E. M. (2022) · eLife · doi:10.7554/elife.69293 · Cited by 49 · see citing works

The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results

Landmark, C. J., Potschka, H., Auvin, S., Wilmshurst, J. M., Johannessen, S. I., Trenité, D. G. A. K.-N., & Wirrell, E. C. (2021) · Epilepsia · doi:10.1111/epi.16849 · Cited by 48 · see citing works

Physical and functional convergence of the autism risk genes Scn2a and Ank2 in neocortical pyramidal cell dendrites

Nelson, A. D., Catalfio, A. M., Gupta, J. P., Min, L. Y., Caballero-Florán, R. N., Dean, K. P., Elvira, C. C., Derderian, K. D., Kyoung, H., Sahagun, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.003 · Cited by 47 · see citing works

RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges

Lee, J. W., Shim, M. K., Kim, H., Jang, H., Lee, Y., & Kim, S. H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115073 · Cited by 46 · see citing works

A zebrafish-centric approach to antiepileptic drug development

Baraban, S. C. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049080 · Cited by 43 · see citing works

RNA-based translation activators for targeted gene upregulation

Cao, Y., Liu, H., Lu, S. S., Jones, K. A., Govind, A. P., Jeyifous, O., Simmons, C. Q., Tabatabaei, N., Green, W. N., Holder, J. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42252-z · Cited by 45 · see citing works

Interneuron-specific dual-AAV SCN1A gene replacement corrects epileptic phenotypes in mouse models of Dravet syndrome

Mich, J. K., Ryu, J., Wei, A. D., Gore, B. B., Guo, R., Bard, A. M., Martinez, R. A., Luber, E. M., Liu, J., Bishaw, Y. M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn5603 · Cited by 61 · see citing works

Epilepsy Genetics and Precision Medicine in Adults: A New Landscape for Developmental and Epileptic Encephalopathies

Beltrán‐Corbellini, Á., Aledo‐Serrano, Á., Møller, R. S., Pérez‐Palma, E., García‐Morales, I., Toledano, R., & Gil‐Nagel, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.777115 · Cited by 44 · see citing works

SCN1A gain‐of‐function mutation causing an early onset epileptic encephalopathy

Clatot, J., Parthasarathy, S., Cohen, S. R., McKee, J. L., Massey, S. L., Somarowthu, A., Goldberg, E. M., & Helbig, I. (2022) · Epilepsia · doi:10.1111/epi.17444 · Cited by 41 · see citing works

Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching

Dawicki-McKenna, J. M., Felix, A. J., Waxman, E. A., Cheng, C., Amado, D. A., Ranum, P. T., Bogush, A., Dungan, L. V., Maguire, J. A., Gagne, A. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38273-3 · Cited by 41 · see citing works

Single-cell long-read sequencing in human cerebral organoids uncovers cell-type-specific and autism-associated exons

Yang, Y., Yang, R., Kang, B., Qian, S., He, X., & Zhang, X. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113335 · Cited by 41 · see citing works

Childhood epilepsy

Menon, R. N., & Cross, J. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00773-1 · Cited by 40 · see citing works

DRAVET ENGAGE. Parent caregivers of children with Dravet syndrome: Perspectives, needs, and opportunities for clinical research

Juandó‐Prats, C., James, E. S., Bilder, D. A., McNair, L. A., Kenneally, N., Helfer, J., Huang, N., Vila, M. C., Sullivan, J. E., Wirrell, E. C., et al. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108198 · Cited by 40 · see citing works

Voltage‐gated sodium channels in genetic epilepsy: up and down of excitability

Rusina, E., Simonti, M., Duprat, F., Cestèle, S., & Mantegazza, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15947 · Cited by 36 · see citing works

Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE / AES Joint Translational Task Force

Auvin, S., Galanopoulou, A. S., Moshé, S. L., Potschka, H., Rocha, L., Walker, M. C., & the TASK1 workgroup on drug‐resistant epilepsy of the ILAE/AES Joint Translational Task Force (2023) · Epilepsia · doi:10.1111/epi.17751 · Cited by 39 · see citing works

Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology

Carvill, G. L., Matheny, T., Hesselberth, J. R., & Demarest, S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01137-z · Cited by 39 · see citing works

Viral vector–mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome

Fadila, S., Beucher, B., Dopeso‐Reyes, I. G., Mavashov, A., Brusel, M., Anderson, K., Ismeurt, C., Goldberg, E. M., Ricobaraza, A., Hernández-Alcoceba, R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci159316 · Cited by 37 · see citing works

Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies—a Study in a Tertiary Epilepsy Center

Bayat, A., Fenger, C., Techlo, T. R., Højte, A. F., Nørgaard, I., Hansen, T. F., Rubboli, G., & Møller, R. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01264-1 · Cited by 38 · see citing works

Challenges and opportunities for precision medicine in neurodevelopmental disorders

Chen, G. T., & Geschwind, D. H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114564 · Cited by 40 · see citing works

Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy

Agbo, J., Ibrahim, Z. G., Magaji, S. Y., Mutalub, Y. B., Mshelia, P. P., & Mhya, D. H. (2023) · Acta Epileptologica · doi:10.1186/s42494-023-00127-2 · Cited by 37 · see citing works

KNa1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons

Gertler, T. S., Cherian, S., DeKeyser, J.-M., Kearney, J. A., & George, A. L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105713 · Cited by 36 · see citing works

Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy

Isom, L. L., & Knupp, K. G. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01095-6 · Cited by 37 · see citing works

Antisense oligonucleotides and their applications in rare neurological diseases

McDowall, S., Aung-Htut, M. T., Wilton, S. D., & Li, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1414658 · Cited by 35 · see citing works

The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives

Specchio, N., Trivisano, M., Aronica, E., Balestrini, S., Arzimanoglou, A. A., Colasante, G., Cross, J. H., Jóźwiak, S., Wilmshurst, J. M., Vigevano, F., et al. (2024) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(24)00196-2 · Cited by 35 · see citing works

Advances in Therapy for Refractory Epilepsy

Jehi, L. E. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-034458 · Cited by 37 · see citing works

Gene therapy in epilepsy

Zhang, L., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112075 · Cited by 34 · see citing works

Caregiver assessment of quality of life in individuals with genetic developmental and epileptic encephalopathies

Cohen, S. R., Helbig, I., Kaufman, M. C., Myers, L. S., Conway, L. J., & Helbig, K. L. (2022) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15187 · Cited by 34 · see citing works

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

Pong, A. W., Ross, J. D. C., Tyrlíková, I., Giermek, A. J., Kohli, M. P., Khan, Y. A., Salgado, R. D., & Klein, P. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2059464 · Cited by 34 · see citing works

Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVI ): II . Drugs in more advanced clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17376 · Cited by 34 · see citing works

Epilepsy in Dravet Syndrome—Current and Future Therapeutic Opportunities

Gao, C., Pielas, M., Jiao, F., Mei, D., Wang, X., Kotulska, K., & Jóźwiak, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072532 · Cited by 34 · see citing works

A Role for Vasoactive Intestinal Peptide Interneurons in Neurodevelopmental Disorders

Goff, K. M., & Goldberg, E. M. (2021) · Developmental Neuroscience · doi:10.1159/000515264 · Cited by 34 · see citing works

Channelopathies in epilepsy: an overview of clinical presentations, pathogenic mechanisms, and therapeutic insights

Ng, A. C., Chahine, M., Scantlebury, M. H., & Appendino, J. P. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12352-x · Cited by 32 · see citing works

Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight

Klein, P., Friedman, D. J., & Kwan, P. (2024) · CNS Drugs · doi:10.1007/s40263-024-01130-y · Cited by 32 · see citing works

Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024) · Epilepsia · doi:10.1111/epi.18075 · Cited by 31 · see citing works

Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments

Debanne, D., Mylonaki, K., Musella, M. L., & Russier, M. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.09.004 · Cited by 32 · see citing works

The dynamic axon initial segment: From neuronal polarity to network homeostasis

Freal, A., & Hoogenraad, C. C. (2025) · Neuron · doi:10.1016/j.neuron.2025.01.004 · Cited by 32 · see citing works

Sodium channel expression and transcript variation in the developing brain of human, Rhesus monkey, and mouse

Heighway, J., Sedó, A., Garg, A., Eldershaw, L., Perreau, V. M., Berecki, G., Reid, C. A., Petrou, S., & Maljevic, S. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105622 · Cited by 32 · see citing works

‘Channeling’ therapeutic discovery for epileptic encephalopathy through iPSC technologies

Simkin, D., Ambrosi, C. M., Marshall, K. A., Williams, L. A., Eisenberg, J., Gharib, M., Dempsey, G. T., George, A. L., McManus, O. B., & Kiskinis, E. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.001 · Cited by 32 · see citing works

Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment

Dwivedi, R., Kaushik, M., Tripathi, M., Dada, R., & Tiwari, P. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149120 · Cited by 30 · see citing works

Zorevunersen in Children and Adolescents with Dravet Syndrome

Laux, L., Sullivan, J., Perry, M. S., Brunklaus, A., Desurkar, A., Schreiber, J. M., Roberts, C. M., Knupp, K. G., Wheless, J. W., Wirrell, E. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2506295 · Cited by 29 · see citing works

Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies

Myers, K. A., & Scheffer, I. E. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-084449 · Cited by 29 · see citing works

Clinical trials for Lennox–Gastaut syndrome: Challenges and priorities

Knowles, J. K., Warren, A. E. L., Mohamed, I., Stafstrom, C. E., Koh, H. Y., Samanta, D., Shellhaas, R. A., Gupta, G., Dixon‐Salazar, T., Tran, L., et al. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52211 · Cited by 28 · see citing works

Intracerebroventricular administration for delivery of antiseizure therapeutics: Challenges and opportunities

Fahoum, F., & Eyal, S. (2023) · Epilepsia · doi:10.1111/epi.17625 · Cited by 28 · see citing works

A comprehensive review of evolving treatment strategies for Dravet syndrome: Insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches

Samanta, D. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.110171 · Cited by 27 · see citing works

Precision therapy in the genetic epilepsies of childhood

Byrne, S., Enright, N., & Delanty, N. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14929 · Cited by 27 · see citing works

CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements

Recinos, Y., Ustianenko, D., Yeh, Y.-T., Wang, X., Jacko, M., Yesantharao, L. V., Wu, Q., & Zhang, C. (2024) · Nature Communications · doi:10.1038/s41467-024-47140-8 · Cited by 25 · see citing works

Antisense oligonucleotides enhance SLC20A2 expression and suppress brain calcification in a humanized mouse model

Zhao, M., Cheng, X., Chen, L., Zeng, Y., Lin, K.-J., Li, Y., Zheng, Z.-H., Xue-jing, H., Zuo, D., Guo, X.-X., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.07.013 · Cited by 25 · see citing works

Genetics and gene therapy in Dravet syndrome

Higurashi, N., Broccoli, V., & Hirose, S. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108043 · Cited by 25 · see citing works

Precision medicine in epilepsy

McGinn, R. J., Stein, E. L. V., Stromberg, J. E. S., & Li, Y. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.04.001 · Cited by 24 · see citing works

Update on Sudden Unexpected Death in Epilepsy

Kløvgaard, M., Sabers, A., & Ryvlin, P. (2022) · Neurologic Clinics · doi:10.1016/j.ncl.2022.06.001 · Cited by 24 · see citing works

Targeting aberrant dendritic integration to treat cognitive comorbidities of epilepsy

Masala, N., Pofahl, M., Haubrich, A. N., Islam, K. U. S., Nikbakht, N., Pasdarnavab, M., Bohmbach, K., Araki, K., Kamali, F., Henneberger, C., et al. (2022) · Brain · doi:10.1093/brain/awac455 · Cited by 24 · see citing works

Are Genetic Therapies for Epilepsy Ready for the Clinic?

Street, J. S., Qiu, Y., & Lignani, G. (2023) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597231176234 · Cited by 23 · see citing works

Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?

Carpenter, J. C., & Lignani, G. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01081-y · Cited by 22 · see citing works

Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease

Odeh, H. M., Fare, C. M., & Shorter, J. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167220 · Cited by 21 · see citing works

Treating Dravet syndrome with TANGO

Crunkhorn, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00153-6

TANGO With SCN1A: Can This Molecular Dance Defeat Dravet Syndrome?

Wagnon, J. L. (2020) · Epiliepsy currents/Epilepsy currents · doi:10.1177/1535759720975750 · Cited by 7 · see citing works

Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome

Lenk, G. M., Jafar‐Nejad, P., Hill, S. F., Huffman, L. D., Smolen, C., Wagnon, J. L., Petit, H. J., Yu, W., Ziobro, J. M., Bhatia, K., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25676 · Cited by 144 · see citing works

Antisense oligonucleotide hope for childhood epilepsies

Fyfe, I. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0319-5 · Cited by 5 · see citing works

Identification of new features and evaluation of antimir-based seizure therapies in the Scn1a(+/-)tm1Kea mouse model of Dravet syndrome

Gerbatin, R. R. (2023) · Figshare · doi:10.25419/rcsi.21551301